WO2015183213A1 - Formes galéniques pharmaceutiques contenant de l'acide n-[4-[[(2,4-diamino-6-ptéridinyl) méthyl]méthylamino]benzoyl]-l-glutamique et de l'acide n-[4-[[(2-amino-3,4-dihydro-4-oxo-6-ptéridinyl)méthyl]méthylamino]benzoyl]-l-glutamique - Google Patents

Formes galéniques pharmaceutiques contenant de l'acide n-[4-[[(2,4-diamino-6-ptéridinyl) méthyl]méthylamino]benzoyl]-l-glutamique et de l'acide n-[4-[[(2-amino-3,4-dihydro-4-oxo-6-ptéridinyl)méthyl]méthylamino]benzoyl]-l-glutamique Download PDF

Info

Publication number
WO2015183213A1
WO2015183213A1 PCT/TR2014/000494 TR2014000494W WO2015183213A1 WO 2015183213 A1 WO2015183213 A1 WO 2015183213A1 TR 2014000494 W TR2014000494 W TR 2014000494W WO 2015183213 A1 WO2015183213 A1 WO 2015183213A1
Authority
WO
WIPO (PCT)
Prior art keywords
glutamic acid
amino
methyl
benzoyl
pteridinyl
Prior art date
Application number
PCT/TR2014/000494
Other languages
English (en)
Inventor
Kader ÇÖMLEKÇİ
Fethi ŞAHİN
Bilgehan ABAY
Özlem YAZIR
Original Assignee
Onko İlaç Sanayi̇ Ve Ti̇caret A. Ş.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onko İlaç Sanayi̇ Ve Ti̇caret A. Ş. filed Critical Onko İlaç Sanayi̇ Ve Ti̇caret A. Ş.
Publication of WO2015183213A1 publication Critical patent/WO2015183213A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Definitions

  • the invention relates to solid,liquid,enteral and parenteral stable combinations of pharmaceutical forms comprising N-[4-[[(2,4-Diamino-6-pteridinyl)methyl] methylamino] benzoyl]-L- glutamic acid (or N-[4-((2,4-Diamino pteridinyl -6-ylmethyl)
  • API II N-[4-[[(2- Amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-L-glutamic acid (or N-(4-(2-Amino-4- hydroxypteridine-6- ylmethyl amino)benzoil)-L(+)-glutamic acid) (hereafter refer to as API II) or pharmaceutically acceptable salts,particulary
  • API I
  • the formulation of the invention relates to a pharmaceutical dosage form and its combination which is not exist in Turkey and the world.
  • EP2046332 describes using 50 mg/ml methotrexate for the treatment of inflammatory autoimmune diseases.
  • EP2046813 describes protein binding methotrexate derivatives and pharmaceutical compositions comprising the methotrexate derivatives.
  • the formulation of the protein binding methotrexate derivative is intended to be used for the treatment of cancer and rheumatic disease.
  • the structural formula which mentioned in the independent claim will be explained in detail in the following;
  • the object of the invention is to provide the use of the most stable pharmaceutical dosage forms that containing API I and API II combination,indicating a long shelf life, used for preventive and therapeutic purpose,increasing patient compliance.
  • the invention relates to solid,liquid,enteral and parenteral stable combinations of pharmaceutical forms comprising N-[4-[[(2,4-Diamino-6-pteridinyl)methyl] methylamino] benzoyl]-L- glutamic acid (or N-[4-((2,4-Diamino pteridinyl -6-ylmethyl)
  • API I is an antineoplastic drug. However, it is used to treat many other diseases unrelated with cancer in lower doses. It is being used via intravenous and higher doses are being used to treat cancer.
  • API I is a cycle specific drug that is showing both antineoplastic and immunosuppressant activity .As an antimetabolite it inhibits dihydrofolate reductase enzyme which is responsible for reduction of API II to tetrahydro structure . Reduction of tetrahydro API II decreases the required level of one-carbon groups and accordingly, purines' ,DNA's and cellular protein synthesis is inhibited.
  • API I is being administered by orally and intravenously. It is well absorbed when given as a low single dose (below 50mg / ml). The absorption is irregular when given above this dosage and it is suitable administering in divided doses. It is completely absorbed when administered by intramuscular injection.
  • BP British Pharmacopoeia
  • USP American Pharmacopoeia
  • API II is a water soluble vitamin B-complex used for oral and parenteral administration. Deficiency can cause various hematological complications including megaloblastic anemia.
  • API II is a biochemically inactive compound that it is precursor of tetrahydrofolic acid and methyltetrahydrofolate. Tetrahydrofolic acid, methyltetrahydrofolate and other folic acid derivatives are necessary substances to sustain erythropoiesis normally. These substances are needed as cofactors for the synthesis of purine and thymidylate nucleic acid. API II and its derivatives are necessary for the conversion of amino acids to each other. API II is given by oral and parenteral administration. Peak levels have been seen within 1 hour.
  • API II is yellow to orange-brown coloured, odorless or very lightly scented crystalline powder.
  • BP British Pharmacopoeia
  • US Pharmacopeia US Pharmacopeia
  • it is very slightly soluble in water; insoluble in alcohol, acetone, chloroform and ether; rapidly soluble in dilute solutions of alkali hydroxides and carbonates; soluble in hydrochloric acid and sulfuric acid.
  • pH range of solution for injection is 8-1 1. It must be protected from light and avoided freezing.
  • Parenteral drugs are given to circulatory system directly or indirectly excepting gastrointestinal system with a syringe as a sterile single dose or multi-dose form of ready to use syringe or vial.
  • the pharmaceutical form is containing N- [4 - [[(2,4-Diamino-6- pteridinyl) methyl] methylamino] benzoyl] -L-glutamic acid (or N- [4 - ((2,4-Diaminopteri pyrimidin-6- ylmethyl) methylamino) benzoyl] -L (+) - glutamic acid) and N- [4 - [[(2- Amino-3,4-dihydro-4-oxo,-6-pteridinyl) methyl] methylamino] benzoyl] -L -glutamic acid (or N- (4- (2-Amino-4-hidroksipteridin-6-ylmethylamino) benzoyl)
  • Production of parenteral solution is comprising the production of small volume parenteral of different volumes of liquid dosage form.
  • Production of parenteral drug can be carried out in the fully automated production line named ready to use syringe filling line.
  • Parenteral solutions are filled into sterile pre-filled syringe, vial or PVC containers.They are administered by injection .
  • parenteral solutions may also be called injectable solutions.
  • injectable solutions must be sterile.
  • the pH of the solution must be equal or close to the pH of body fluids (7.4).
  • Osmolality of the solution must be isosmotic with body fluids or close to them.
  • lt must not contain pyrogen which has bacterial lipopolysaccharide structure and can cause fever (should be apyrogenic ).
  • the solution must not contain particulate matter (micro or macroparticle).
  • Parenteral treatment is administering therapeutic agents by other than gastrointestinal system.
  • fluid and electrolytes, vitamins, sugars, protein, blood or components, vaccines, several drugs for therapeutic or diagnostic purposes can be administered.
  • the pharmaceutical effect starts faster than oral route. Drugs which can not be absorbed easily and degraded in the digestive tract can be given in this way.
  • Parenteral administration is preferred when it is desired to act quickly, the patient can not take the drug orally
  • the way of administration is determined by the suitability of the vessel, the patient's choices and preferences of the physician.For instance; Although the irritant drugs administered intramuscularly, easily absorbable drugs such as insulin are given by subcutaneously. Effect starts quickly and continues during the desired time. Sterile preparations are produced in clean room conditions for helping to minimize the risk of pyrogenic and particulate matter. Quality assurance of these requirements in sterile manufacturing has great importance and this manufacturing process must be carried out according to the validated production methods and procedures.
  • the solution is prepared in class A environment which has a background of class B environment.
  • class A environment which has a background of class B environment.
  • parenteral drugs are manufactured generally in the form of ready to use syringes or vials in a single dose or rarely multidose, it can be mentioned two types of production process: Usually the issue depends on the education and behavior of the staff.
  • WFI water for injection
  • WFI 80-90% of water for injection is loaded into the reactor.
  • WFI is cooled gradually 50 ° C then 40 ° C. Cooling is performed by flowing WFI which is passing through opposite direction in the coil .
  • the solution is made isotonic or isohydric.Osmotic pressure of the solution is adjusted up to the pressure of body fluids.
  • the volume of solution (final volume in the recipe) is completed with water for injection.
  • Solution is stirred in accordance with the processes for production program. Dissolved oxygen in the solution is removed by sending nitrogen continuously during stirring.
  • the solution preparation process ends when dissolved oxygen completely removed by passing through nitrogen.
  • Solution is passed through firstly 0,45 ⁇ then 0.22 ⁇ membrane filter and samples are taken for analysis.lt is filtered in this way and samples are taken for the following in- process controls.
  • Sending the inert gas such as nitrogen continuously during the preparation process in the production tank is performed to provide removing oxygen and also mechanical stirring of the solution and mixing gas flow .Thus, a complete dissolution and homogeneity is obtained.
  • In-process controls are performed after preparation of the solution.
  • the solution is filtered 0.45 ⁇ and 0.22 ⁇ membrane filter with nitrogen respectively.
  • Filtered product is sent to filling line storage reactor. Preparation for filling and filling are performed after appropriate analysis results.
  • the present invention is formed based on these features of the formulation more detailed below.
  • Stable formulation for cancer and supportive care is established by using production methods mentioned above with API I and API II as active ingredients and the following excipients.
  • API I and API II forms because of their high solubility.
  • the ratio and the order of addition of buffering agents in the manufacturing process is determined to provide dissolving of the combination of the active ingredients.
  • Solubilizing and buffering agent in the pharmaceutical form sodium hydroxide is selected from sodium carbonate and derivatives.
  • Strong acid or alkali solutions cause damage in the area where they are injected.
  • Adjusting the pH is needed to increase the stability of the drug, prevent tissue pain, damage and irritation at the injection site, prevent the growth of microorganisms and increase physiological activity.
  • the reason of the pH changing is degradation of drug and substances that contaminated from glass or plastics containers and stoppers. Buffer solutions are used if the drug is degraded out of stable pH range.
  • buffering agent must be compatible with the drug.Injectable dosage form is desirable to adjust the pH using a suitable buffering agent. pH of the blood is between 7.3-7.5. The injected solution is at the same pH with plasma to prevent pain and irritation. Blood has a buffer capacity. pH adjusment may not be needed because of rapid dilution when intravenous solutions are injected very slowly
  • Priority is the stability of the preparation. This is why the pH of the solution is adjusted to 7.5 to 9.0 which the active agent is stable.
  • Chelating agent is added to protect patients from the toxicity of metal ions and make active ingredients stable. These stable combined pharmaceutical form can be applied parenterally, when we prefer to use a chelating agent; as edetic acid or edetate disodium hydrate, sodium, calcium disodium, dipotassium, cobalt, disodium, trisodium, disodium and derivatives .For any reason very low concentrations of heavy metals in the environment can accelerate oxidation. Therefore, chelating agents are being used to hold these substances. They generate stable water-soluble complexes.
  • a chelating agent as edetic acid or edetate disodium hydrate, sodium, calcium disodium, dipotassium, cobalt, disodium, trisodium, disodium and derivatives .
  • Isotonicity agent is added to the formula not to cause any damage to the patients' cells.
  • Isotonicity agent can be selected as sodium chloride,mannitol and- derivatives in this stable parenteral combined pharmaceutical form.
  • Isotonic solutions have equivalent pressure to the osmotic pressure of blood plasma. Hypotonic solution has lower osmotic pressure than the osmotic pressure of the blood plasma and the solution which has more osmotic pressure is called hypertonic solutions.
  • Sterile parenteral pharmaceutical preparation is equal to body pH (7.4) or close to it, preferably should be isotonic and pyrogen free.
  • the solution is desired to be isotonic to reduce the damage of the parenteral drug to the tissue and maintain the blood electrolyte balance.
  • Osmotic pressure of the solution (osmolality) is expressed in units of osmole / kg.
  • the solution which has lower osmotic pressure from body fluids or 0.9% NaCl is hypotonic. It causes hemolysis of erythrocytes.
  • the solution which has more osmotic pressure from body fluid is hypertonic and it causes constriction of erythrocytes. Any cosolvent or surfactan are not required because of the active substance is dissolved.
  • the solvent used during production in unit formula is water for injection and it is suitable for preparing parenteral solutions.
  • the raw material of the injection water is deionized water known as WPU.WPU is obtained by distillation by passing through the water heat exchanger at 96 ° C to 102 ° C. Pyrogenic substances substantially purified in this water.
  • the Water for Injection (WFI) obtained from the autoclave sterilization with contacting with water vapor.This sterilization is identified SIP (sterilization in place) and the process is carried out in situ sterilization.
  • Combined stable aqueous solution comprising API I and API II is filled into glass vials and use pre-filled syringe for parenteral use. Both filtration and terminal sterilization were administered. Parenteral solutions is maintained at 121 0 C for 15-20 minutes in autoclave sterilization.
  • Parenteral solutions must be sterile because of directly injected to people. Sterility is absence of living organisms such as bacteria and fungi which are reproduced in standard culture media.Sterilization is the destruction of these organisms.
  • Parenteral solutions are kept at 121 ° C during 15 to 20 minutes in autoclave sterilization.
  • Parenteral solution that unstable to the heat sterilization is filtered through membrane filters which is made of cellulose esters and derivatives and has undefined pore size . 0.22 ⁇ pore size filters are efficient for the removal of very small organisms.
  • Ready to use syringes are small primary packaging containers that made of glass, plastic, polymer or copolymer materials which drug or drug solvent is filled for parenteral purpose.Pre-filled syringe and vial containers should not contain any extractable substances that may change stability and increase toxicity of the product.
  • Stability is related to shelf life of the product. Time dependent changing of bacterial or chemical compound in the solution is undesired . Therefore stability enhancers and preservatives are added to the parenteral dosage forms.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des combinaisons stables solides, liquides, entérales et parentérales de formes pharmaceutiques comprenant de l'acide N-[4-[[(2,4-diamino-6-ptéridinyl)méthyl]méthylamino] benzoyl]-L-glutamique et de l'acide N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-ptéridinyl)méthyl]méthylamino]benzoyl]-L-glutamique, leurs sels pharmaceutiquement acceptables, en particulier le monohydrate de sodium et de disodium, en tant qu'ingrédients actifs.
PCT/TR2014/000494 2014-05-28 2014-12-09 Formes galéniques pharmaceutiques contenant de l'acide n-[4-[[(2,4-diamino-6-ptéridinyl) méthyl]méthylamino]benzoyl]-l-glutamique et de l'acide n-[4-[[(2-amino-3,4-dihydro-4-oxo-6-ptéridinyl)méthyl]méthylamino]benzoyl]-l-glutamique WO2015183213A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201405970 2014-05-28
TR2014/05970 2014-05-28

Publications (1)

Publication Number Publication Date
WO2015183213A1 true WO2015183213A1 (fr) 2015-12-03

Family

ID=52596587

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2014/000494 WO2015183213A1 (fr) 2014-05-28 2014-12-09 Formes galéniques pharmaceutiques contenant de l'acide n-[4-[[(2,4-diamino-6-ptéridinyl) méthyl]méthylamino]benzoyl]-l-glutamique et de l'acide n-[4-[[(2-amino-3,4-dihydro-4-oxo-6-ptéridinyl)méthyl]méthylamino]benzoyl]-l-glutamique

Country Status (1)

Country Link
WO (1) WO2015183213A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2046332A2 (fr) 2006-07-21 2009-04-15 medac Gesellschaft für klinische Spezialgeräte mbH Solutions de méthotrexate concentrées
EP2046813A2 (fr) 2006-07-28 2009-04-15 medac Gesellschaft für klinische Spezialgeräte mbH Dérivés de méthotrexate de liaison protéique et médicaments contenant lesdits dérivés
US20110280932A1 (en) * 2010-05-13 2011-11-17 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2046332A2 (fr) 2006-07-21 2009-04-15 medac Gesellschaft für klinische Spezialgeräte mbH Solutions de méthotrexate concentrées
EP2046813A2 (fr) 2006-07-28 2009-04-15 medac Gesellschaft für klinische Spezialgeräte mbH Dérivés de méthotrexate de liaison protéique et médicaments contenant lesdits dérivés
US20110280932A1 (en) * 2010-05-13 2011-11-17 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DULAL C. CHATTERJI ET AL: "Thermal and photolytic decomposition of methotrexate in aqueous solutions", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 67, no. 4, 1 April 1978 (1978-04-01), pages 526 - 531, XP055180778, ISSN: 0022-3549, DOI: 10.1002/jps.2600670422 *
HIGNITE C E ET AL: "SEPARATION AND IDENTIFICATION OF IMPURITIES IN PARENTERAL METHOTREXATE DOSAGE FORMS", CANCER TREATMENT REPORTS, vol. 62, no. 1, 1978, pages 13 - 18, XP008175793, ISSN: 0361-5960 *
JOSEPH F. GALLELLI ET AL: "Assay of methotrexate in the presence of its decomposition products and other folic acid analogs", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 56, no. 3, 1 March 1967 (1967-03-01), pages 387 - 389, XP055180854, ISSN: 0022-3549, DOI: 10.1002/jps.2600560317 *
VINCKE B J ET AL: "Extended stability of 5-fluorouracil and methotrexate solutions in PVC containers", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 54, no. 3, 15 September 1989 (1989-09-15), pages 181 - 189, XP023736092, ISSN: 0378-5173, [retrieved on 19890915], DOI: 10.1016/0378-5173(89)90095-1 *

Similar Documents

Publication Publication Date Title
JP5522877B2 (ja) モキシフロキサシン／塩化ナトリウム製剤
EP1948133B1 (fr) Formulation d'argatroban contenant une acide comme agent solubilisant
US9572887B2 (en) Formulations of bendamustine
JP7178731B2 (ja) ビオプテリン誘導体を含む固体薬学的組成物およびそのような組成物の使用
JP6892494B2 (ja) パラセタモール及びイブプロフェンを含む水性配合物
TWI544934B (zh) 含有氟喹諾酮抗生素藥物之經改良藥學組成物
KR101843613B1 (ko) 약제학적 페메트렉시드 액제
WO2013179310A1 (fr) Compositions aqueuses stables de pémétrexed
JP2017514924A (ja) シクロホスファミド液状濃縮物の製剤
EP2666463A1 (fr) Composition liquide stabilisée comprenant du pemetrexed
KR20180066239A (ko) 단트롤렌을 포함하는 수성 조성물
JP2020125359A (ja) ペメトレキセドまたはその薬剤学的に許容可能な塩を含有する安定化された薬学組成物
CN110464846B (zh) 一种美洛昔康组合物、制剂及其制备方法与应用
WO2015183213A1 (fr) Formes galéniques pharmaceutiques contenant de l'acide n-[4-[[(2,4-diamino-6-ptéridinyl) méthyl]méthylamino]benzoyl]-l-glutamique et de l'acide n-[4-[[(2-amino-3,4-dihydro-4-oxo-6-ptéridinyl)méthyl]méthylamino]benzoyl]-l-glutamique
WO2014083071A1 (fr) Préparation liquide injectable consistant en une combinaison de tramadol et de paracétamol
WO2014007239A1 (fr) Composition contenant de l'amphotéricine b
JP2000219628A (ja) アラトロフロキサシンの予め混合した注射用組成物
WO2016071784A1 (fr) Compositions comprenant de la finafloxacine et du tris
WO2023183055A1 (fr) Formulations d'hydromorphone prêtes à l'emploi
RU2545903C1 (ru) Фармацевтическая композиция в виде лиофилизата для приготовления раствора для парентерального применения и способ ее получения
EP2934524B1 (fr) Formulations vétérinaires injectables de pénéthamate
WO2020077564A1 (fr) Solution d'injection de téniposide ayant une bonne stabilité de dilution et son procédé de préparation
WO2014139677A1 (fr) Préparation parentérale d'agent antibactérien à base de fluoroquinolone et procédé de préparation associé
US20130096163A1 (en) Injectable dosage form of flupirtine
WO2000067753A1 (fr) Formulation parenterale de 5-(2-chloroethyle)-4-methylthiazole edisylate(clomethiazole edisylate)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14841373

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14841373

Country of ref document: EP

Kind code of ref document: A1